Question 1

How much would I have if I DCA'd $100/week into CRL for 5 years?

Accepted Answer

Dollar cost averaging $100 per week into CRL for 5 years (261 purchases) would have resulted in a total investment of $26,100 and a current value of $38,546, a return of 48%. Using Enhanced DCA, which concentrates buys during dips, the same $100/week base deployed $51,607 and grew to $80,737 — a 56% return.

Question 2

What is the best DCA strategy for CRL?

Accepted Answer

Backtesting shows Enhanced DCA — which increases buy amounts during market dips and reduces or skips buys when CRL is overextended — outperformed standard weekly DCA by 9% over 5 years. The enhanced strategy achieved a 56% return vs 48% for standard DCA.

Question 3

What would $100/week into CRL be worth after 3 years?

Accepted Answer

Investing $100 per week into CRL for 3 years (157 purchases, $15,700 total) would have grown to $25,309 — a 61% return. Enhanced DCA over the same period returned 79%.

Question 4

Is DCA into CRL worth it?

Accepted Answer

Based on a 5-year backtest, DCA into CRL returned 48% with standard weekly purchases. An intelligent DCA strategy that buys more during dips returned 56% over the same period — a 9% gain in return, while deploying more capital.

Question 5

How many shares of CRL would I have after DCA for 5 years?

Accepted Answer

Dollar cost averaging $100/week into CRL for 5 years would result in approximately 128 shares with a standard DCA approach (avg entry $204). Enhanced DCA targeting dips results in 268 shares at an average entry of $193.

Question 6

How does CRL DCA compare to the S&P 500?

Accepted Answer

Enhanced DCA into CRL returned 56% over the past 5 years. The S&P 500 (SPY) returned approximately 53% over the same period. CRL's performance reflects its volatility as a healthcare asset. Enhanced DCA outperformed standard DCA by 9%, demonstrating the value of intelligent entry timing during market dips.

Question 7

What is the risk of dollar cost averaging into CRL?

Accepted Answer

Past backtest performance does not guarantee future results. CRL is a healthcare asset whose price can fall as well as rise. While DCA reduces timing risk by spreading purchases over time, losses are still possible if the price declines significantly. Always invest within your risk tolerance and consider your overall portfolio diversification.

Question 8

What is the Charles River Laboratories dollar cost averaging strategy?

Accepted Answer

Standard DCA invests a fixed amount ($100/week or $433/month) into CRL at regular intervals. Enhanced DCA improves on this by using RSI (Relative Strength Index) signals to increase buy amounts during market dips (oversold conditions) and reduce or skip purchases when the stock is overextended. Over the 5-year backtest, this timing approach has delivered 9% higher returns than standard DCA while deploying more total capital into CRL.

Period	Standard DCA	Enhanced DCA	Alpha
1-Year	54%	88%	+35%
3-Year	61%	79%	+18%
5-Year	48%	56%	+9%

CRL DCA Backtest — Dollar Cost Averaging Results

CRL DCA Results: Key Findings

Alpha you missed while unsubscribed

Dollar cost averaging into CRL — backtest results

Buying the dips for Charles River Laboratories